168 related articles for article (PubMed ID: 34423904)
1. A randomized, multicenter trial assessing the effects of rapastinel compared to ketamine, alprazolam, and placebo on simulated driving performance.
Su S; Kay G; Hochadel T; Rojo J; Christopher Stein J; Boinpally R; Periclou A
Clin Transl Sci; 2022 Jan; 15(1):255-266. PubMed ID: 34423904
[TBL] [Abstract][Full Text] [Related]
2. Glutamatergic receptor and neuroplasticity in depression: Implications for ketamine and rapastinel as the rapid-acting antidepressants.
Wang YT; Zhang NN; Liu LJ; Jiang H; Hu D; Wang ZZ; Chen NH; Zhang Y
Biochem Biophys Res Commun; 2022 Feb; 594():46-56. PubMed ID: 35074585
[TBL] [Abstract][Full Text] [Related]
3. The effects of intranasal esketamine (84 mg) and oral mirtazapine (30 mg) on on-road driving performance: a double-blind, placebo-controlled study.
van de Loo AJAE; Bervoets AC; Mooren L; Bouwmeester NH; Garssen J; Zuiker R; van Amerongen G; van Gerven J; Singh J; der Ark PV; Fedgchin M; Morrison R; Wajs E; Verster JC
Psychopharmacology (Berl); 2017 Nov; 234(21):3175-3183. PubMed ID: 28755104
[TBL] [Abstract][Full Text] [Related]
4. Positive N-Methyl-D-Aspartate Receptor Modulation by Rapastinel Promotes Rapid and Sustained Antidepressant-Like Effects.
Donello JE; Banerjee P; Li YX; Guo YX; Yoshitake T; Zhang XL; Miry O; Kehr J; Stanton PK; Gross AL; Burgdorf JS; Kroes RA; Moskal JR
Int J Neuropsychopharmacol; 2019 Mar; 22(3):247-259. PubMed ID: 30544218
[TBL] [Abstract][Full Text] [Related]
5. GLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice.
Rajagopal L; Burgdorf JS; Moskal JR; Meltzer HY
Behav Brain Res; 2016 Feb; 299():105-10. PubMed ID: 26632337
[TBL] [Abstract][Full Text] [Related]
6. Effects of alprazolam on driving ability, memory functioning and psychomotor performance: a randomized, placebo-controlled study.
Verster JC; Volkerts ER; Verbaten MN
Neuropsychopharmacology; 2002 Aug; 27(2):260-9. PubMed ID: 12093599
[TBL] [Abstract][Full Text] [Related]
7. Esketamine and rapastinel, but not imipramine, have antidepressant-like effect in a treatment-resistant animal model of depression.
Pereira VS; Joca SRL; Harvey BH; Elfving B; Wegener G
Acta Neuropsychiatr; 2019 Oct; 31(5):258-265. PubMed ID: 31230597
[TBL] [Abstract][Full Text] [Related]
8. Next-day residual effects of gabapentin, diphenhydramine, and triazolam on simulated driving performance in healthy volunteers: a phase 3, randomized, double-blind, placebo-controlled, crossover trial.
Kay GG; Schwartz HI; Wingertzahn MA; Jayawardena S; Rosenberg RP
Hum Psychopharmacol; 2016 May; 31(3):217-26. PubMed ID: 27018419
[TBL] [Abstract][Full Text] [Related]
9. Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression.
Yang B; Zhang JC; Han M; Yao W; Yang C; Ren Q; Ma M; Chen QX; Hashimoto K
Psychopharmacology (Berl); 2016 Oct; 233(19-20):3647-57. PubMed ID: 27488193
[TBL] [Abstract][Full Text] [Related]
10. Driving Simulator Performance After Administration of Analgesic Doses of Ketamine With Dexmedetomidine or Fentanyl.
Hayley AC; Downey LA; Green M; Shiferaw B; Kenneally M; Keane M; Adams M; Shehabi Y
J Clin Psychopharmacol; 2019; 39(5):446-454. PubMed ID: 31433347
[TBL] [Abstract][Full Text] [Related]
11. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults.
McCloud TL; Caddy C; Jochim J; Rendell JM; Diamond PR; Shuttleworth C; Brett D; Amit BH; McShane R; Hamadi L; Hawton K; Cipriani A
Cochrane Database Syst Rev; 2015 Sep; (9):CD011611. PubMed ID: 26415966
[TBL] [Abstract][Full Text] [Related]
12. Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Dean RL; Hurducas C; Hawton K; Spyridi S; Cowen PJ; Hollingsworth S; Marquardt T; Barnes A; Smith R; McShane R; Turner EH; Cipriani A
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD011612. PubMed ID: 34510411
[TBL] [Abstract][Full Text] [Related]
13. Rapastinel, an NMDAR positive modulator, produces distinct behavioral, sleep, and EEG profiles compared with ketamine.
Banerjee P; Donello JE; Hare B; Duman RS
Behav Brain Res; 2020 Aug; 391():112706. PubMed ID: 32461133
[TBL] [Abstract][Full Text] [Related]
14. The acute and residual effects of escalating, analgesic-range doses of ketamine on driving performance: A simulator study.
Hayley AC; Green M; Downey LA; Stough CKK; Keane M; Shiferaw B; Kostakis P; Shehabi Y
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Aug; 86():83-88. PubMed ID: 29782960
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate CA; Singh JB; Carlson PJ; Brutsche NE; Ameli R; Luckenbaugh DA; Charney DS; Manji HK
Arch Gen Psychiatry; 2006 Aug; 63(8):856-64. PubMed ID: 16894061
[TBL] [Abstract][Full Text] [Related]
16. Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controls.
Pearlman EM; Wilbraham D; Dennehy EB; Berg PH; Tsai M; Doty EG; Kay GG
Hum Psychopharmacol; 2020 Sep; 35(5):e2732. PubMed ID: 32449213
[TBL] [Abstract][Full Text] [Related]
17. Rapastinel, a novel glutamatergic agent with ketamine-like antidepressant actions: Convergent mechanisms.
Kato T; Duman RS
Pharmacol Biochem Behav; 2020 Jan; 188():172827. PubMed ID: 31733218
[TBL] [Abstract][Full Text] [Related]
18. Ascending-Dose Study of Controlled-Release Ketamine Tablets in Healthy Volunteers: Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability.
Glue P; Medlicott NJ; Surman P; Lam F; Hung N; Hung CT
J Clin Pharmacol; 2020 Jun; 60(6):751-757. PubMed ID: 32065415
[TBL] [Abstract][Full Text] [Related]
19. Glutamatergic Signaling Drives Ketamine-Mediated Response in Depression: Evidence from Dynamic Causal Modeling.
Gilbert JR; Yarrington JS; Wills KE; Nugent AC; Zarate CA
Int J Neuropsychopharmacol; 2018 Aug; 21(8):740-747. PubMed ID: 29668918
[TBL] [Abstract][Full Text] [Related]
20. Rapastinel - an investigational NMDA-R modulator for major depressive disorder: evidence to date.
Ragguett RM; Rong C; Kratiuk K; McIntyre RS
Expert Opin Investig Drugs; 2019 Feb; 28(2):113-119. PubMed ID: 30585524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
